EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow EYPT
EyePoint, Inc. (EYPT) Piotroski F-score
EyePoint, Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | (1.00) |
| FY2024 | 4 | (2.00) |
| FY2023 | 6 | 3.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | (1.00) |
| FY2020 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (59.29%) | (33.83%) | Fail | 0 |
| Positive operating cash flow | (240.11m) | (126.23m) | Fail | 0 |
| Rising return on assets | (59.29%) | (33.83%) | Fail | 0 |
| Cash flow above net income | (8.15m) | 4.64m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 8.88 | 7.81 | Pass | 1 |
| No new shares issued | 73,251,000 | 56,298,000 | Fail | 0 |
| Rising gross margin | 93.41% | 91.42% | Pass | 1 |
| Rising asset turnover | 0.08 | 0.11 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| IPSC Century Therapeutics, Inc. compare | 4 |
| EYPT EyePoint, Inc. | 3 |
| OCGN Ocugen, Inc. compare | 2 |
| ABEO Abeona Therapeutics Inc. compare | — |
| PRLD Prelude Therapeutics Incorporated compare | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| XFOR X4 Pharmaceuticals, Inc. compare | — |
| CABA Cabaletta Bio, Inc. compare | — |
| PALI Palisade Bio, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover